TITLE:
ABX-EGF (a Monoclonal Antibody) Given to Patients With Prostate Cancer With or Without Tumor in Other Parts of the Body

CONDITION:
Prostate Cancer

INTERVENTION:
ABX-EGF

SUMMARY:

      A clinical trial examining the safety and effectiveness of ABX-EGF when given to patients
      with prostate cancer with or without tumor in other parts of the body.

      Patients will be treated for a maximum of 48 doses (6 treatment courses; 8 doses per course)
      or until evidence of progressive disease.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: Male
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Male 18 years of age or older

          -  Has tumor tissue available for diagnostics

          -  Failed front line luteinizing hormone-releasing hormone analogue (LHRH) such as
             leuprolide or goserelin, or failed orchiectomy, as evidenced by disease progression.
             Patients must continue on a LHRH analogue (unless the patient had an orchiectomy)
             throughout the course of the study

          -  ECOG score of 0 or 1

        Exclusion Criteria:

          -  Any prior chemotherapy for prostate cancer besides hormonal therapy (including no
             prior EGFr targeting agent)

          -  Prior history of cancer other than prostate carcinoma within the past 5 years that
             has required treatment or been active (prior basal cell carcinoma is allowed)

          -  Known to be HIV positive

          -  Myocardial infarction within one year prior to entering the study
      
